Blood thiol status and erythrocyte glutathione-S-transferase in chronic kidney disease patients on treatment with frequent (daily) hemodialysis

Free Radical Research

Volumn 48, Issue 3, 2014, Pages 273-281

  Galli, F ^a   Piroddi, M ^a   Bartolini, D ^a   Ciffolilli, S ^a   Buoncristiani, E ^b   Ricci, G ^c   Buoncristiani, U ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Nephrology Unit   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Blood thiols; Daily hemodialysis; Glutathione; Glutathione S transferase; Homocysteine; Uremic toxins

Indexed keywords

CYSTEINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HOMOCYSTEINE; THIOL; THIOL DERIVATIVE;

ADULT; ARTICLE; BLOOD CHEMISTRY; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DETOXIFICATION; ERYTHROCYTE; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLASMA; YOUNG ADULT; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; ENZYMOLOGY; METABOLISM; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK FACTOR;

CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ERYTHROCYTES; FEMALE; GLUTATHIONE TRANSFERASE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; SULFHYDRYL COMPOUNDS;

EID: 84893594913     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2013.861901     Document Type: Article

References (51)

1. Prakash M, Upadhya S, Prabhu R. Protein thiol oxidation and lipid peroxidation in patients with uraemia. Scand J Clin Lab Invest 2004; 64: 599-604.
2. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538.
3. Khazim K, Giustarini D, Rossi R, Verkaik D, Cornell JE, Cunningham SE, et al. Glutathione redox potential is low and glutathionylated and cysteinylated hemoglobin levels are elevated in maintenance hemodialysis patients. Transl Res 2013; 162: 16-25.
4. Alhamdani MS. Impairment of glutathione biosynthetic pathway in uraemia and dialysis. Nephrol Dial Transplant 2005; 20: 124-128.
5. Galli F, Piroddi M, Annetti C, Aisa C, Floridi E, Floridi A. Oxidative stress and reactive oxygen species. Contrib Nephrol 2005; 149: 240-260.
6. Esposito MG, Cesare CM, De Santo RM, Cice G, Perna AF, Violetti E, et al. Parathyroidectomy improves the quality of sleep in maintenance hemodialysis patients with severe hyperparathyroidism. J Nephrol 2008; 21: S92 - S96.
7. Lathem WW, Bergsbaken T, Witowski SE, Perna NT, Welch RA. Acquisition of stcE, a C1 esterase inhibitor-specific metalloprotease, during the evolution of Escherichia coli O157:H7. J Infect Dis 2003; 187: 1907-1914.
8. Perla-Kajan J, Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids 2007; 32: 561-572.
9. Mann JF, Sheridan P, McQueen MJ, Held C, Arnold JM, Fodor G, et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease - results of the renal Hope-2 study. Nephrol Dial Transplant 2008; 23: 645-653.
10. Canestrari F, Buoncristiani U, Galli F, Giorgini A, Albertini MC, Carobi C, et al. Redox state, antioxidative activity and lipid peroxidation in erythrocytes and plasma of chronic ambulatory peritoneal dialysis patients. Clin Chim Acta 1995; 234: 127-136.
11. Apeland T, Kristensen O, Mansoor MA. The aminothiol redox status in haemodialysis patients does not improve with folate therapy. Scand J Clin Lab Invest 2009; 69: 265-271.
12. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000; 58: 2571-2578.
13. Matsuyama Y, Terawaki H, Terada T, Era S. Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease. Clin Exp Nephrol 2009; 13: 308-315.
14. Alvarez B, Carballal S, Turell L, Radi R. Formation and reactions of sulfenic acid in human serum albumin. Methods Enzymol 2011; 473: 117-136.
15. Rappaport SM, Li H, Grigoryan H, Funk WE, Williams ER. Adductomics: Characterizing exposures to reactive electrophiles. Toxicol Lett 2012; 213: 83-90.
16. Gomez SA, Fernandez GC, Camerano G, Dran G, Rosa FA, Barrionuevo P, et al. Endogenous glucocorticoids modulate neutrophil function in a murine model of haemolytic uraemic syndrome. Clin Exp Immunol 2005; 139: 65-73.
17. Mitrogianni Z, Barbouti A, Galaris D, Siamopoulos KC. Oxidative modifi cation of albumin in predialysis, hemodialysis, and peritoneal dialysis patients. Nephron Clin Pract 2009; 113: C234 - c240.
18. Piroddi M, Palazzetti I, Quintaliani G, Pilolli F, Montaldi M, Valentina V, et al. Circulating levels and dietary intake of the advanced glycation end-product marker carboxymethyl lysine in chronic kidney disease patients on conservative predialysis therapy: A pilot study. J Ren Nutr 2011; 21: 329-339.
19. Canestrari F, Galli F, Giorgini A, Albertini MC, Galiotta P, Pascucci M, Bossu M. Erythrocyte redox state in uremic anemia: Eff ects of hemodialysis and relevance of glutathione metabolism. Acta Haematol 1994; 91: 187-193.
20. Galli F, Rovidati S, Benedetti S, Buoncristiani U, Covarelli C, Floridi A, Canestrari F. Overexpression of erythrocyte glutathione S-transferase in uremia and dialysis. Clin Chem 1999; 45: 1781-1788.
21. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005; 45: 51-88.
22. Awasthi YC, Ansari GA, Awasthi S. Regulation of 4-hydroxynonenal mediated signaling by glutathione S-transferases. Methods Enzymol 2005; 401: 379-407.
23. Cimolai N, Blair GK, Murphy JJ, Fraser GG. Impact of infection by verotoxigenic Escherichia coli O157:H7 on the use of surgical services in a children ' s hospital. Can J Surg 1997; 40: 28-32.
24. Oakley AJ, Lo Bello M, Nuccetelli M, Mazzetti AP, Parker MW. The ligandin (non-substrate) binding site of human Pi class glutathione transferase is located in the electrophile binding site (H-site). J Mol Biol 1999; 291: 913-926.
25. Vasieva O. The many faces of glutathione transferase pi. Curr Mol Med 2011; 11: 129-139.
26. Manevich Y, Hutchens S, Tew KD, Townsend DM. Allelic variants of glutathione S-transferase P1-1 diff erentially mediate the peroxidase function of peroxiredoxin VI and alter membrane lipid peroxidation. Free Radic Biol Med 2013; 54: 62-70.
27. Ralat LA, Manevich Y, Fisher AB, Colman RF. Direct evidence for the formation of a complex between 1-cysteine peroxiredoxin and glutathione S-transferase pi with activity changes in both enzymes. Biochemistry 2006; 45: 360-372.
28. Manevich Y, Feinstein SI, Fisher AB. Activation of the antioxidant enzyme 1-CYS peroxiredoxin requires glutathionylation mediated by heterodimerization with pi GST. Proc Natl Acad Sci USA 2004; 101: 3780-3785.
29. Shipman AR, Jones SE, Smith G, Stewart B, McCarthy N. A case of verocytotoxin-producing Escherichia coli O157 from a private barbecue in South East England. Euro Surveill 2009; 14: Pii: 19273.
30. Townsend DM, Manevich Y, He L, Hutchens S, Pazoles CJ, Tew KD. Novel role for glutathione S-transferase pi. Regulator of protein S-Glutathionylation following oxidative and nitrosative stress. J Biol Chem 2009; 284: 436-445.
31. Noce A, Ferrannini M, Fabrini R, Bocedi A, Dessi M, Galli F, et al. Erythrocyte glutathione transferase: A new biomarker for hemodialysis adequacy, overcoming the Kt/V(urea) dogma? Cell Death Dis 2012; 3: E377.
32. Dessi M, Noce A, Dawood KF, Galli F, Taccone-Gallucci M, Fabrini R., et al. Erythrocyte glutathione transferase: A potential new biomarker in chronic kidney diseases which correlates with plasma homocysteine. Amino Acids 2012; 43: 347-354.
33. Ikizler TA, Flakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during hemodialysis. Kidney Int 1994; 46: 830-837.
34. Navarro JF, Mora C, Leon C, Martin-Del Rio R, Macia ML, Gallego E, et al. Amino acid losses during hemodialysis with polyacrylonitrile membranes: Eff ect of intradialytic amino acid supplementation on plasma amino acid concentrations and nutritional variables in nondiabetic patients. Am J Clin Nutr 2000; 71: 765-773.
35. Smolin LA, Laidlaw SA, Kopple JD Altered plasma free and protein-bound sulfur amino acid levels in patients undergoing maintenance hemodialysis. Am J Clin Nutr 1987; 45: 737-743.
36. Galli F, Benedetti S, Buoncristiani U, Piroddi M, Conte C, Canestrari F, et al. The eff ect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int 2003; 64: 748-755.
37. Yavuz A, Tetta C, Ersoy FF, D ' Intini V, Ratanarat R, De Cal M, et al. Uremic toxins: A new focus on an old subject. Semin Dial 2005; 18: 203-211.
38. Piroddi M, Bartolini D, Ciff olilli S, Galli F. Non-dialysable uremic toxins. Blood Purif 2013; 35: 30-41.
39. Floridi A, Antolini F, Galli F, Fagugli RM, Floridi E, Buoncristiani U. Daily haemodialysis improves indices of protein glycation. Nephrol Dial Transplant 2002; 17: 871-878.
40. Giustarini D, Dalle-Donne I, Lorenzini S, Selvi E, Colombo G, Milzani A, et al. Protein thiolation index (PTI) as a biomarker of oxidative stress. Free Radic Biol Med 2012; 53: 907-915.
41. Galli F, Rossi R, Di Simplicio P, Floridi A, Canestrari F. Protein thiols and glutathione infl uence the nitric oxide-dependent regulation of the red blood cell metabolism. Nitric Oxide 2002; 6: 1 86-1 99.
42. Giustarini D, Dalle-Donne I, Lorenzini S, Milzani A, Rossi R. Age-related infl uence on thiol, disulfi de, and protein-mixed disulfi de levels in human plasma. J Gerontol A Biol Sci Med Sci 2006; 61: 1030-1038.
43. Zwaginga JJ, IJsseldijk MJ, de Groot PG, Kooistra M, Vos J, van Es A, et al. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma. Thromb Haemost 1991; 66: 638-647.
44. Kielstein JT, Boger RH, Bode-Boger SM, Martens- Lobenhoff er J, Lonnemann G, Frolich JC, et al. Low dialysance of asymmetric dimethylarginine (ADMA) - in vivo and in vitro evidence of signifi cant protein binding. Clin Nephrol 2004; 62: 295-300.
45. Vene R, Castellani P, Delfi no L, Lucibello M, Ciriolo MR, Rubartelli A. The cystine/cysteine cycle and GSH are independent and crucial antioxidant systems in malignant melanoma cells and represent druggable targets. Antioxid Redox Signal 2011; 15: 2439-2453.
46. Vanholder R, Schepers E, Meert N, Lameire N. What is uremia? Retention versus oxidation. Blood Purif 2006; 24: 33-38.
47. Galli F. Protein damage and infl ammation in uraemia and dialysis patients. Nephrol Dial Transplant 2007; 22: V20 - v36.
48. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 2009; 22: 636-643.
49. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005; 16: 1471-1485.
50. Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R. Behavior of non-protein-bound and proteinbound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002; 40: 339-347.
51. Fagugli RM, Vanholder R, De Smet R, Selvi A, Antolini F, Lameire N, et al. Advanced glycation end products: Specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis. Int J Artif Organs 2001; 24: 256-262.